Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

View Full Size 

Download

• Full Size JPEG, 1222x427, 85.8 KB
• Small JPEG, 480x168, 29.2 KB
• Preview JPEG, 144x50, 7.6 KB
• Thumbnail JPEG, 120x42, 6.2 KB